Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure (EAGLE)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Sanofi
ClinicalTrials.gov Identifier:
NCT01117350
First received: May 4, 2010
Last updated: March 5, 2014
Last verified: March 2014

May 4, 2010
March 5, 2014
July 2010
October 2012   (final data collection date for primary outcome measure)
Percentage of Patients Whose Glycosylated Haemoglobin (HbA1c) <7% at the End of the Comparative Period [ Time Frame: week 12, week 24 ] [ Designated as safety issue: No ]
The value at the end of the comparative period was defined as the last available HbA1c value measured during the comparative period plus 14 days after the last dose of Investigational Product (i.e. last-observation-carried-forward [LOCF] value).
Percentage of patients whose Glycosylated Haemoglobin (HbA1c) <7% [ Time Frame: at the end of the comparative period (at week 24) ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01117350 on ClinicalTrials.gov Archive Site
  • Percentage of Patients Whose Glycosylated Haemoglobin (HbA1c) Has Decreased But Remains ≥7% at the End of the Comparative Period [ Time Frame: baseline (week -2), week 12, week 24 ] [ Designated as safety issue: No ]

    Percentage of patients with:

    * HbA1c value at end of the comparative period (LOCF) lower than HbA1c baseline value

    AND

    * HbA1c value at end of the comparative period (LOCF) ≥7%

  • Percentage of Patients Whose Glycosylated Haemoglobin (HbA1c) Has Increased at the End of the Comparative Period [ Time Frame: baseline (week -2), week 12, week 24 ] [ Designated as safety issue: No ]
    Percentage of patients with HbA1c value at end of the comparative period (LOCF) higher than HbA1c baseline value
  • Glycosylated Haemoglobin (HbA1c): Change From Baseline to the End of Comparative Period [ Time Frame: baseline (week -2), week 12, week 24 ] [ Designated as safety issue: No ]
    Change in HbA1C from baseline to the last observation carried forward (LOCF) measured during the comparative period = LOCF value - baseline value
  • Glycosylated Haemoglobin (HbA1c): Change From Beginning to the End of the Extension Period [ Time Frame: week 24, week 36, week 48 ] [ Designated as safety issue: No ]
    Change in HbA1C from beginning of the extension period (week 24) to the last observation carried forward (LOCF) measured during the extension period = LOCF value - week 24 value
  • Percentage of Patients Whose Glycosylated Haemoglobin (HbA1c) <7% at the End of the Extension Period [ Time Frame: week 36, week 48 ] [ Designated as safety issue: No ]
    Value at the end of the extension period defined as last available HbA1c value measured during the extension period (i.e. last observation carried forward (LOCF) value)
  • Self-Monitored Fasting Plasma Glucose (SMFPG) Measurements: Change From Baseline to the End of the Comparative Period [ Time Frame: baseline (week 0), week 6, week 12, week 18, week 24 ] [ Designated as safety issue: No ]

    SMFPG = mean value of Self-Monitored Fasting Plasma Glucose measurements over 3 consecutive days in the week before each visit

    Value at the end of the comparative period defined as last available value during the comparative period (i.e. last-observation-carried-forward [LOCF] value)

    Change = LOCF value - baseline value

  • Self-Monitored Fasting Plasma Glucose (SMFPG) Measurements: Change From Beginning to the End of the Extension Period [ Time Frame: week 24, week 30, week 36, week 48 ] [ Designated as safety issue: No ]

    SMFPG = mean value of Self-Monitored Fasting Plasma Glucose measurements over 3 consecutive days in the week before each visit

    Value at the end of the extension period defined as last available value during the extension period (i.e. last-observation-carried-forward [LOCF] value)

    Change = LOCF value - week 24 value

  • Self-Monitored 7-point Plasma Glucose (PG) Profile: Change From Baseline to the End of the Comparative Period [ Time Frame: baseline (week 0), week 12, week 24 ] [ Designated as safety issue: No ]

    Self-monitored 7-point plasma glucose profiles (before and 2 hours after the start of breakfast, lunch and dinner, and at bedtime) recorded on 3 consecutive days in the week before each visit

    Value at the end of the comparative period defined as last available value during the comparative period (i.e. last-observation-carried-forward [LOCF] value)

    Change = LOCF value - baseline value

  • Self-Monitored 7-point Plasma Glucose (PG) Profile: Change From Beginning to the End of the Extension Period [ Time Frame: week 24, week 36, week 48 ] [ Designated as safety issue: No ]

    Self-monitored 7-point plasma glucose profiles (before and 2 hours after the start of breakfast, lunch and dinner, and at bedtime) recorded on 3 consecutive days in the week before each visit

    Value at the end of the extension period defined as last available value during the extension period (i.e. last-observation-carried-forward [LOCF] value)

    Change = LOCF value - week 24 value

  • Body Weight: Change From Baseline to the End of the Comparative Period [ Time Frame: baseline (week 0), week 2, week 6, week 12, week 18, week 24 ] [ Designated as safety issue: No ]
    Change = Last weight value measured during the comparative period (LOCF value) - weight value at baseline
  • Body Weight: Change From Beginning to End of the Extension Period [ Time Frame: week 24, week 30, week 36, week 48 ] [ Designated as safety issue: No ]
    Change = Last weight value measured during the extension period (LOCF value) - weight value at beginning of the Extension Period (Week 24)
  • Daily Dose of Insulin Glargine [ Time Frame: week 1, week 2, week 6, week 12, week 24 ] [ Designated as safety issue: No ]
  • Daily Dose of Liraglutide [ Time Frame: week 1, week 2, week 6, week 12, week 24 ] [ Designated as safety issue: No ]
  • Daily Dose of Insulin Glargine Administered During the Extension Period [ Time Frame: week 30, week 36, week 48 ] [ Designated as safety issue: No ]
  • Hypoglycemia Occurence: Number of Patients With at Least One Episode of Symptomatic / Severe Symptomatic Hypoglycemia During the Comparative Period [ Time Frame: all across the comparative period (from week 0 to week 24) ] [ Designated as safety issue: Yes ]

    Symptomatic hypoglycemia was defined as an event with clinical symptoms that were considered to result from hypoglycemia.

    Severe symptomatic hypoglycemia was defined as an event with clinical symptoms that were considered to result from hypoglycemia, requiring the assistance of another person for active administration of carbohydrate, glucagon or other countermeasure because the patient could not treat him/herself due to acute neurological impairment directly resulting from the hypoglycemia (assistance by another person when the patient could have treated him/herself was not considered as requiring assistance)and one of the following criteria:

    • The event was associated with a measured PG level < 36 mg/dL (2 mmol/L),
    • Or, in absence of PG value, the event was associated with neurological recovery attributable to the restoration of PG to normal, after oral carbohydrate, intravenous glucose or glucagon administration.
  • Hypoglycemia Occurence: Number of Patients With at Least One Episode of Symptomatic / Severe Symptomatic Hypoglycemia During the Extension Period [ Time Frame: all across the extension period (from week 24 to week 48) ] [ Designated as safety issue: Yes ]

    Symptomatic hypoglycemia was defined as an event with clinical symptoms that were considered to result from hypoglycemia.

    Severe symptomatic hypoglycemia was defined as an event with clinical symptoms that were considered to result from hypoglycemia, requiring the assistance of another person for active administration of carbohydrate, glucagon or other countermeasure because the patient could not treat him/herself due to acute neurological impairment directly resulting from the hypoglycemia (assistance by another person when the patient could have treated him/herself was not considered as requiring assistance)and one of the following criteria:

    • The event was associated with a measured PG level < 36 mg/dL (2 mmol/L),
    • Or, in absence of PG value, the event was associated with neurological recovery attributable to the restoration of PG to normal, after oral carbohydrate, intravenous glucose or glucagon administration.
  • Percentage of patients whose Glycosylated Haemoglobin (HbA1c) has decreased but remains ≥7% [ Time Frame: at the end of the comparative period (at week 24) ] [ Designated as safety issue: No ]
  • Percentage of patients whose Glycosylated Haemoglobin (HbA1c) has increased [ Time Frame: at the end of the comparative period (at week 24) ] [ Designated as safety issue: No ]
  • Glycosylated Haemoglobin (HbA1c) [ Time Frame: at screening (week-2), at visit 10 (week 12) and visit 12 (week 24) for the comparative period and at visit 20 (week 36) and visit 22 (week 48) for the extension period ] [ Designated as safety issue: No ]
  • Evaluation of Self-monitored 7-point PG (plasma glucose) profile [ Time Frame: over 3 consecutive days in the week prior to baseline (week 0), visit 10 (week 12) and visit 12 (week 24) for the comparative period and prior to visit 20 (week 36) and visit 22 (week 48) for the extension period ] [ Designated as safety issue: No ]
    measured immediately before and 2 hours after breakfast, lunch and dinner and at bedtime
  • Self-monitored Fasting Plasma Glucose (FPG) measurements [ Time Frame: over 3 consecutive days in the week prior to visit 7 (week 6) and visit 11 (week 18) for the comparative period and prior to visit 17 (week 30) for the extension period ] [ Designated as safety issue: No ]
  • Vital signs: body weight measures [ Time Frame: At baseline (week 0), visit 4 (week 2), visit 7 (week 6), visit 10 (week 12), visit 11 (week 18) and visit 12 (week 24) for the comparative period and at visit 17 (week 30), at visit 20 (week 36) and visit 22 (week 48) for the extension period ] [ Designated as safety issue: No ]
  • Hypoglycemia occurence [ Time Frame: all across the comparative and extension periods (from week 1 to 48) ] [ Designated as safety issue: No ]
  • Dose of insulin glargine or of liraglutide [ Time Frame: At each visit from visit 3 (week 1) to visit 12 (week 24). ] [ Designated as safety issue: No ]
  • Dose of insulin glargine [ Time Frame: at each visit from visit 13 (week 25) to visit 22 (week 48) for the extension period. ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure
A 24-week, Multicenter, International, Randomized (1:1), Parallel-group, Open-label, Comparative Study of Insulin Glargine Versus Liraglutide in Insulin-naïve Patients With Type 2 Diabetes Treated With Oral Agents and Not Adequately Controlled, Followed by a 24-week Extension Period With Insulin Glargine for Patients Not Adequately Controlled With Liraglutide

Primary objective:

To demonstrate the superiority of insulin glargine over liraglutide in terms of percentage of patients reaching a Glycosylated Haemoglobin (HbA1c) < 7% at the end of the comparative period (24 weeks) in Type 2 diabetic patients failing lifestyle management and oral agents

Secondary objectives of the comparative period (24 weeks):

>To assess the effect of insulin glargine in comparison with liraglutide on:

  • HbA1c level
  • Percentage of patients whose HbA1c has decreased but remains >= 7% at the end of the comparative period
  • Percentage of patients whose HbA1c has increased at the end of the comparative period
  • Fasting Plasma Glucose (FPG)
  • 7-point Plasma Glucose (PG) profiles
  • Hypoglycemia occurrence
  • Body weight
  • Adverse events

Objectives of the extension period (24 weeks):

>To assess the effect of insulin glargine in patients not adequately controlled with liraglutide on:

  • HbA1c level
  • FPG
  • 7-point PG profiles
  • Hypoglycemia occurrence
  • Body weight
  • Adverse events

Maximum estimated study duration per patient: either 27 weeks (patients randomized to insulin glargine arm) or 51 weeks (patients randomized to liraglutide arm) broken down as follow:

  • A 2-week of screening period,
  • A 24-week comparative period,
  • A 24-week extension period (only for patients treated with liraglutide, not adequately controlled at the end of the comparative period),
  • A 1-week follow-up period
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Diabetes Mellitus, Type 2
  • Drug: Insulin glargine
    100 Units/mL solution for injection in a pre-filled SoloStar pen
    Other Name: Lantus®
  • Drug: Liraglutide
    6 mg/mL solution for injection in a 3-mL pre-filled pen (18mg)
    Other Name: Victoza®
  • Drug: Metformin
    Metformin was a background treatment, mandatory for each patient randomized in the study (at the minimum dose of 1g/day). It was not supplied by the sponsor.
  • Experimental: Insulin Glargine

    Insulin glargine administered once a day, in the morning or in the evening, at the most convenient time. The time of injection, once chosen was to remain unchanged during the whole duration of the study.

    The starting dose was 0.2 Unit per kilogram of body weight or 10 Units. Patients were empowered to adjust their insulin doses, under strict investigator's supervision. Insulin titration (by 2 or 4 Units) was done every 3 days according to the median value of Fasting Plasma Glucose (FPG) of the last 3 days. The goal was to achieve 70 < FPG ≤ 100 mg/dL (3.9 < FPG ≤ 5.5 mmol/L). Minor deviations from the titration scheme could be allowed, based on Investigator's judgment and patient's situation.

    Interventions:
    • Drug: Insulin glargine
    • Drug: Metformin
  • Active Comparator: Liraglutide

    Liraglutide administered once a day, in the morning or in the evening, at the most convenient time. The time of injection , once chosen was to remain unchanged during the whole duration of the study.

    The dose was 0.6 mg/day during the first week, 1.2 mg/day during the second week and 1.8 mg/day until week 24. The dose might be decreased to 1.2 mg for safety reasons (e.g. gastro-intestinal tolerability), based on Investigator's judgment.

    Interventions:
    • Drug: Liraglutide
    • Drug: Metformin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
978
March 2013
October 2012   (final data collection date for primary outcome measure)

Inclusion criteria (comparative period):

  • Patients With Type 2 Diabetes diagnosed for at least 1 year,
  • Treated with lifestyle interventions and metformin at the maximum tolerated dosage (with a minimum daily dosage of 1g), either alone or in combination with an oral insulin secretagogue (sulfonylurea, glinide or DiPeptidyl Peptidase IV inhibitor), for more than 3 months,
  • 7.5% < HbA1c <= 12%,
  • Body Mass Index (BMI) between 25 and 40 kg/m2 inclusively,
  • Ability and willingness to perform PG (Plasma Glucose) self monitoring using the sponsor-provided glucose meter and to complete the patient diary,
  • Willingness and ability to comply with the study protocol,
  • Signed informed consent obtained prior to any study procedure.

Inclusion criteria (extension period):

  • Patients treated with liraglutide (at the maximal tolerated dosage), having a mean FPG ≥ 250 mg/dL at visit 10 (Week 12) or visit 11 (Week 18), or a HbA1c≥ 7% at visit 12 (Week 24)
  • Dosage of metformin compliant with the inclusion criteria of visit 1 (i.e. maximum tolerated dosage, with a minimum daily dosage of 1g), and maintained stable during the comparative period.

Exclusion criteria:

  • Previous treatment with Glucagon Like Peptide-1 analogues or insulin in the past year (except in case of temporary treatment for gestational diabetes, surgery, hospitalization...),
  • Treatment with thiazolidinediones or α-Glucosidases inhibitors within 3 months prior to study entry,
  • Diabetes other than Type 2 diabetes (e.g. secondary to pancreatic disorders, drug or chemical agents intake),
  • Pregnant women (women of childbearing potential must have a negative pregnancy test at study entry and a medically approved contraceptive method),
  • Lactating women,
  • Hospitalized patients (except hospitalization for routine diabetes check-up),
  • Active proliferative retinopathy, as defined by a photocoagulation or vitrectomy occurrence in the 6 months prior to study entry, or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgical treatment during the study, documented by a retina examination within 2 years prior to study entry,
  • Impaired renal function (creatinine clearance < 60 mL/mn),
  • Impaired hepatic function (Alanine Aminotransferase, Aspartate Aminotransferase 2.5 times the upper limit of normal range),
  • Personal or family history of medullary thyroid carcinoma,
  • Multiple endocrine neoplasia syndrome type 2,
  • Severe gastro-intestinal disease (including inflammatory bowel disease or diabetic gastroparesis),
  • Congestive heart failure,
  • History of acute pancreatitis,
  • Treatment with corticosteroids with potential systemic action for more than 10 days within 3 months prior to study entry,
  • Alcohol or drug abuse in the past 5 years,
  • History of sensitivity to the study drugs or to drugs with a similar chemical structure.
  • Night shift worker,
  • Presence of any condition (medical, psychological, social or geographical), current or anticipated that would compromise the patients safety or limit the patient successful participation in the study,
  • Participation in a clinical trial (drug or device) within 3 months prior to study entry,
  • Refusal or inability to give informed consent to participate in the study,
  • Patient is the Investigator or any sub-Investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.

Additional exclusion criteria for the extension period:

  • Treatment with oral antidiabetic drugs other than metformin and patient's usual sulfonylurea if any, or with insulin during the comparative period (except in case of an emergency, for a period of time less than 7 days),
  • Treatment with corticosteroids with potential systemic action within the last 3 months of the comparative period.
  • History of sensitivity to insulin glargine.
Both
35 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Austria,   Brazil,   Canada,   Czech Republic,   Finland,   France,   Greece,   Ireland,   Israel,   Mexico,   Netherlands,   Russian Federation,   Slovakia,   Spain,   Sweden,   Turkey
 
NCT01117350
LANTU_C_03680, 2010-018437-21, U1111-1116-9684
Not Provided
Sanofi
Sanofi
Not Provided
Study Director: Clinical Sciences & Operations Sanofi
Sanofi
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP